– First-in-Human PERK inhibitor (HC-5404) to be developed in combination with AVEO's FOTIVDA® (tivozanib) for RCC – – AVEO obtains option to an exclusive license for the development, manufacturing, and commercialization of HC-5404 – BOSTON, Nov. 4, 2025 /PRNewswire/ -- AVEO Oncology, an LG Chem company (AVEO), and HiberCell, Inc. (HiberCell) announced today that the companies have entered into an exclusive development and option agreement to develop HiberCell's first-in-human human protein kin

BRONX, N.Y., Nov. 4, 2025 /PRNewswire/ -- LeMed Specialty Pharmacy, a nationally recognized provider of specialty patient care, today announced a strategic collaboration with Free Market Health (FMH), the definitive technology platform transforming the specialty pharmacy ecosystem, aimed at enhancing the experience for individuals living with rare and complex conditions. Through this collaboration, LeMed will leverage FMH's innovative platform to streamline access coordination between physicians

SALT LAKE CITY, Nov. 4, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced the presentation of a poster Treatment with Oral LPCN 2401, a Physiological Regulator of Myostatin, Rapidly Improves Body Composition in Men with Obesity at the ObesityWeek® annual meeting, taking place in Atlanta, Ga., November 4 to 7. The poster features 20-week data f

STOCKHOLM, Nov. 4, 2025 /PRNewswire/ -- Calliditas Therapeutics (Calliditas), an Asahi Kasei company, announced today that new data will be presented at the 2025 American Society of Nephrology Kidney Week, taking place from November 6 to 9 in Houston, Texas. The presentations will include new secondary analyses from the Phase 3 NefIgArd study of Nefecon (marketed as TARPEYO® [budesonide] delayed-release capsules in the United States in patients with primary immunoglobulin A nephropathy [IgAN] wh

Six new studies from DaVita Clinical Research spotlight improved outcomes with GLP-1 use, advancements in treatments, transplant access and end-of-life care DENVER and HOUSTON, Nov. 4, 2025 /PRNewswire/ -- DaVita, a steadfast leader in kidney care research and innovation, is unveiling six new studies at the American Society of Nephrology's (ASN) Kidney Week 2025, taking place Nov. 5-9 in Houston, Texas. These studies reflect DaVita's ongoing commitment to advancing kidney treatment through da

PRINCETON, N.J., Nov. 4, 2025 /PRNewswire/ - Medunik USA, a specialty pharmaceutical company dedicated to providing rare disease patients with access to orphan drugs, and part of Duchesnay Pharmaceutical Group (DPG), winner of the 2024 Life Sciences Innovation Award by ADRIQ, is pleased to announce that Pheburane® (sodium phenylbutyrate) is now covered under Preferred Medicaid Programs in 19 states, while 29 states offer it under Medicaid Programs with limited or no restrictions. Additionally, P

- New preclinical data to show anti-tumor activity of ATNM-400 in hormone-resistant and HER2-resistant breast cancer, addressing the need for new treatment options beyond tamoxifen and trastuzumab - ATNM-400 demonstrates efficacy across prostate cancer, non-small cell lung cancer (NSCLC), and breast cancer - three of the largest oncology indications - with potential as monotherapy, in combination, or as an alternative therapy NEW YORK, Nov. 4, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.

AmacaThera receives US$5 million upfront and up to US$225 million in potential future milestone payments with Pacira BioSciences for AMT-143, AmacaThera's long-acting non-opioid anesthetic for post-operative pain AMT-143 leverages AmacaThera's breakthrough tunable hydrogel platform, delivering sustained local release of ropivacaine AmacaThera and Pacira will collaborate on the Phase 2 clinical program, and Pacira will fund clinical development, manufacturing, and commercialization ,

BEIJING, Nov. 4, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has entered into an Agreement and Plan of Merger (the "Merger Agreement") with Oceanpine Skyline Inc. ("Parent") and Oceanpine Merger Sub Inc. ("

Adds to the Previously Granted Patents Covering the Use of REQORSA in Combination with Immune Checkpoint Inhibitors Strengthens Patent Estate and Provides Additional Protection in Large Market AUSTIN, Texas, Nov. 4, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the European Patent Office (EPO) has communicated its int